Trinity Bio is a biotechnology company focused on developing innovative therapies and diagnostics for various medical conditions. The company leverages advanced technologies to create solutions aimed at enhancing patient care and improving health outcomes. By prioritizing research and development, Trinity Bio strives to bring cutting-edge products to market that address unmet medical needs, while also engaging in partnerships and collaborations within the healthcare sector to expand its reach and efficacy in the industry.
Trinity Biotech stock surges on high volume after announcing increased orders for TrinScreen HIV, boosting 2024 revenue projections to $10 million. Second-quarter earnings show a 14% YoY revenue increase driven by strong HIV test sales.
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion. AMD shares dipped 3.8% to $165.49 on Wednesday.
